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Novelty and Impact: the tumor-stroma ratio is a prognostic parameter for predicting clinical 
outcome. Here, the authors showed that the prognostic value of the tumor-stroma ratio is  
most discriminative in patients with grade III or triple negative breast cancer. The prognostic 
effect of the tumor-stroma ratio was not altered by other clinically relevant parameters thus 
making it a potential valuable factor to improve risk stratification, for example, in online 






















The tumor-stroma ratio (TSR) was evaluated as a promising parameter for breast cancer 
prognostication in clinically relevant subgroups of patients. The TSR was assessed on 
hematoxylin and eosin stained tissue slides of 1794 breast cancer patients from the 
Nottingham City Hospital. An independent second cohort of 737 patients from the 
Netherlands Cancer Institute to Antoni van Leeuwenhoek was used for evaluation. In the 
Nottingham Breast Cancer series, the TSR was an independent prognostic parameter for 
recurrence-free survival (RFS) (HR 1.35, 95% CI 1.10 to 1.66, p = 0.004). The interaction 
term was statistically significant for grade and triple-negative status. Multivariate Cox 
regression analysis showed a more pronounced effect of the TSR for RFS in grade III tumors 
(HR 1.89, 95% CI 1.43 to 2.51, p < 0.001) and triple-negative tumors (HR 1.86, 95% CI 1.10 
to 3.14, p = 0.020). Comparable hazard ratios and confidence intervals were observed for 
grade and triple-negative status in the ONCOPOOL study. The prognostic value of TSR was 
not modified by age, tumor size, histology, estrogen receptor status, progesterone receptor 
status, human epidermal growth factor receptor 2 status or lymph node status. In conclusion, 
patients with a stroma-high tumor had a worse prognosis compared to patients with a stroma-
low tumor. The prognostic value of the TSR is most discriminative in grade III tumors and 
triple-negative tumors. The TSR was not modified by other clinically relevant parameters 



































Breast cancer mortality rates are declining in most European countries due to early detection 
and improved treatment options (1). Optimizing risk stratification to prevent under- and over-
treatment by personalizing therapy is thereby essential.  
In the last decade, the interplay of tumor cells and its microenvironment has gained increased 
interest. The tumor microenvironment, also known as tumor associated stroma, consists of 
immune cells, fibroblasts, pericytes and endothelial cells in an extracellular matrix. The 
tumor microenvironment plays an active role in creating an environment that favors the 
tumor cells; increased motility of cells, suppression of the immune response, remodeling of 
the extracellular matrix and angiogenesis (2-6).  
A promising prognostic parameter based on the tumor associated stroma is the tumor-stroma 
ratio (TSR). The TSR reflects the amount of tumor stroma to the cancer cells, which is 
determined on routinely retrieved hematoxylin and eosin (H&E) stained tissue slides used for 
pathological assessment of surgically removed breast tissue. TSR assessment is easy, quick 
and without additional costs. Previous research demonstrated the prognostic value of the TSR 
in different types of invasive solid tumors, including breast cancer (7-32). Most of these 
studies validated a worse prognosis for patients with stroma-high tumors. 
Breast cancer is a heterogeneous disease, which makes subgroup analysis essential. Kramer et 
al. reviewed literature published on the prognostic value of TSR in the general breast cancer 
population and different clinically important subgroups (33). Here, we set out to validate the 
effect of the TSR and further expand its utility in the clinically relevant subgroups for breast 
cancer prognostication. This is an essential step towards prospective validation and clinical 
implementation, such as the addition of TSR to the frequently used online prediction tool 
PREDICT. 
 




The Nottingham Breast Cancer series from Nottingham City Hospital (UK) 
The study population consists of women of ≤70 years with primary invasive breast cancer 
without distant metastases, diagnosed and treated primarily with surgery in the Nottingham 
City Hospital between 1993 and 2002 (n = 1809). This cohort was retrospectively assembled. 
Patients were included if digital H&E slides of the primary breast tumors and follow to up 
data were available. Exclusion criteria were breast cancer in premedical history and/or 
neoadjuvant treatment.  
 
The ONCOPOOL study from the Netherlands Cancer Institute to Antoni van Leeuwenhoek 
(the Netherlands) 
A total of 737 women treated primarily with surgery for invasive non-metastasized breast 
cancer between 1990 and 1999, included in the ONCOPOOL study at The Netherlands 
Cancer Institute-Antoni van Leeuwenhoek hospital, were analyzed in this study. The included 
patients were part of the larger ONCOPOOL database of European primary breast cancer 
patients. Details on data management and patient selection were described previously (14, 
34). Survival data, estrogen receptor (ER) status, progesterone receptor (PR) status are 
updated since the previous publication on tumor-stroma ratio according to the last publication 




All patient data were used in an anonymized manner and data were handled according to 
national ethical guidelines (“Code for Proper Secondary Use of Human Tissue”, Dutch 
Federation of Medical Scientific Societies”). No additional informed consent was required. 
The Nottingham Breast Cancer Series was approved by the Nottingham Research Ethics 
Committee 2 under the title ‘Development of molecular genetic classification of breast 
cancer’.  
 
Assessment of the tumor-stroma ratio  
In the Nottingham Breast Cancer series, the TSR was visually assessed on digital H&E 
stained slides of the primary breast tumor via CaseViewer 2.2 for Windows (3DHISTECH 
Ltd., Budapest, Hungary), a digital application for the evaluation of microscopic images. The 
original 4 µm routine H&E stained slides were scanned into high-resolution (0.19 µm/pixel) 
digital images at 20x magnification using 3DHistech Panoramic 250 Flash II scanner 
(3DHISTECH Ltd., Budapest, Hungary). Firstly, the whole tissue slide was visually 
evaluated for the orientation of the most stromal rich field. Secondly, the most stromal 
abundant area was annotated using a circle with an area of 3.1 mm2. This microscopic field is 
comparable with the surface selected with a 10x objective of most light microscopes and 
corresponds with the magnification used in previously (36). All slides were double scored in 
a blinded fashion (KV,WM). A third observer (DC) was consulted if consensus could not be 
reached. The tissue slide with the highest stroma percentage was decisive in cases where 
multiple slides were available per patient. Stromal areas suspected for post-biopsy effects 
were excluded from TSR assessment.  
The TSR assessment on tumor tissue of patients included in the ONCOPOOL study was 
assessed using visual microscopy on conventional H&E slides (14).  
The TSR was scored by the method of Mesker et al. in both cohorts (7). A percentage of 
≤50% stroma was categorized as stroma-low and >50% stroma was categorized as stroma-
high (supplementary figure 1).  
 
Statistical analyses 
Statistical analyses were performed using IBM SPSS statistics (version 23 for Windows). The 
recurrence-free survival (RFS), the primary endpoint, was defined as the time between the 
date of diagnosis and local, regional or distant recurrence. Patients who died without a 
recurrence were censored. Breast cancer-specific survival (BCSS), the secondary endpoint in 
the Nottingham Breast Cancer series, was defined as the time from date of diagnosis and 
breast cancer-specific death. The BCSS was not available for the ONCOPOOL study.  
Therefore in this cohort, the overall survival (OS) was used as the second endpoint. The OS 
was defined as the time from diagnosis to death from any cause. 
The X2 test was used to evaluate the difference between categorical variables in stroma-low 
and stroma-high groups. Fisher’s exact test was performed if less than five patients were 
included per category and Fisher-Freeman-Halton when the table was larger than 2x2. The 
Kaplan-Meier method and the log-rank test were performed. Cohen’s kappa coefficient was 
used to test inter-observer variability. 
The Cox regression model was used to perform univariate and multivariate analysis. In the 
multivariate Cox regression analysis of the Nottingham Breast Cancer series, the TSR and 
confounders were entered; age at diagnosis (continuous), grade (I,II or III), size (≤2 cm and 
>2 cm), histological type (invasive carcinoma of no special type (NST), lobular carcinoma, 
tubular carcinoma and others), ER status (negative or positive), PR status (negative or 
positive), human epidermal growth factor receptor 2 (HER2) status (negative or positive). 
These analyses were also performed with triple-negative status as a variable instead of ER 
status, PR status and HER2 status. Also, lymph node status was entered in the multivariate 
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Cox regression in addition to standard confounders as described above, as lymph node status 
is not a confounder but a clinically important parameter. A p-value <0.05 was considered as 
statistical significant. The univariate and multivariate Cox regression analysis of the 
ONCOPOOL study were also performed as described in the original report of Roeke et al., to 
check reproducibility. For the evaluation of the prognostic value of the TSR for clinically 
relevant subgroups, the interaction term was introduced in the Cox regression analysis. This 
was corrected for clinically relevant confounders as described above.  
 
Data availability  






The Nottingham Breast Cancer series 
A total of 2385 H&E slides of 1809 patients were assessed for TSR. The slides of 15 (0.8%) 
patients were not eligible for TSR scoring due to the poor quality of the tissue. The Cohen’s 
kappa coefficient was 0.61 between two observers, which corresponds with a substantial to a 
good level of agreement. Due to the digital learning curve, slides with an incongruent value 
were individually assessed by the same observers for a second time (blinded from their first 
scores). Cohen’s kappa coefficient in the total cohort increased up to 0.87, which corresponds 
with an almost perfect level of agreement. The H&E slides of 37 patients were discussed with 
a third observer. A final agreement for the TSR was reached in all cases. A total of 1794 
patients were suitable for statistical analysis. The median age at the time of diagnosis was 55 
years (range 23–70 years), and the median follow-up period was 11 years (range 0-18 years). 
Table 1 provides an overview of patient and tumor characteristics.  
 
The ONCOPOOL study 
The ONCOPOOL study included 737 women with breast cancer and was previously analyzed 
for the prognostic value of the TSR (14). The median age at inclusion was 54 (range 23-71 
years). The median follow to up was 12 years (range 0-24 years). Patient, tumor and 
treatment characteristics are shown in supplementary table 1. 
 
The prognostic value of the TSR  
In the total study population of the Nottingham Breast Cancer series, 681 (38%) patients were 
categorized in the stroma-low group and 1113 (62%) patients in the stroma-high group. Table 
1 shows the statistically significant differences between both stroma categories. Age, tumor 
size, lymph node involvement, ER status and triple-negative tumors were significantly 
different between both stromal categories.  
The Kaplan-Meier analysis and the log-rank test for RFS showed a statistical significant 
different outcome between patients with a stroma-low and stroma-high tumor in favor of 
patients with stroma-low tumors (supplementary figure 2). The TSR was an independent 
prognostic parameter in favor of patients with stroma-low tumors for both RFS and BCSS 
when adjusted for different sets of confounders (table 2 and table 3) 
Since the ONCOPOOL study was updated, the prognostic value of the TSR was evaluated 
again. The analyses showed that patients with a tumor with a high stromal content had a 
worse survival, in the total cohort as well as in subgroups. The results from the multivariate 
Cox regression analysis of the updated database were comparable with those of the original 
observations; RFS HR 1.35, 95% CI 1.01 to 1.79, p = 0.040 versus HR 1.35, 95% CI 1.01 to 
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1.81, p = 0.046 and OS HR 1.46, 95% CI 1.13 to 1.88, p = 0.003 versus HR 1.56, 95% CI 
1.18 to 2.05, p = 0.002, respectively (data not shown). When the TSR was adjusted for 
confounders, the OS showed a statistically significant difference in favor for stroma-low 
tumors. The results for the RFS were borderline statically significant (supplementary table 2 
and supplementary table 3) 
 
TSR stratified by clinically important subgroups  
In Cox regression analysis, the interaction term was introduced, to evaluate the prognostic 
effect in different clinically important subgroups.  
In the Nottingham Breast Cancer series, the interaction term showed a statistically significant 
p-value for grade (p < 0.001 and p = 0.002) and triple-negative status (p = 0.040 and p = 
0.026) for RFS and BCSS, respectively. No statistically significant results for RFS and BCSS 
were observed if stratified for age, tumor size, histology, ER status, PR status, HER2 status 
and lymph node status. The prognostic value of the TSR calculated by multivariate Cox 
regression analysis showed the most discriminative effect of the TSR in grade III tumors 
compared to grade I and grade II tumors, and in triple-negative tumors compared to non-
triple-negative tumors, for RFS and BCSS (table 4). Kaplan-Meier analysis and log-rank test 
for RFS of the TSR stratified by grade and triple-negative status showed a statistically 
significant difference between subgroups (figure 1 and figure 2). 
The ONCOPOOL study was used to validate the survival effects in grade III tumors and 
triple-negative tumors. The interaction term for grade (p = 0.122) and triple-negative status (p 
= 0.343) was not significant for RFS. The Hazard Ratio (HR) of the prognostic effect of the 
TSR for RFS were most discriminative in grade III tumors compared to grade I and grade II. 
If stratified by triple-negative status, the HR of the TSR in non-triple-negative tumours was 
lower compared to triple-negative tumors, but this was not statistically significant. The 
interaction term was not statistically significant if stratified by age, tumor size, histology, ER 




In this study, we evaluated the prognostic value of TSR in, to our knowledge, the largest 
cohort published on the prognostic value of TSR in breast cancer. The number of patients 
offered the opportunity to perform analyses of clinically relevant subgroups for breast cancer 
prognostication and treatment.  
Firstly, patients with a stroma-high tumor had a worse prognosis compared to patients with a 
stroma-low tumor. Secondly, the results of the Nottingham Breast Cancer series showed that 
the prognostic effect of the TSR was most discriminative in grade III tumors, compared to 
grade I and grade II tumors, and in triple-negative tumors, compared to non-triple-negative 
tumors. In the ONCOPOOL study, the HRs and confidence intervals of the TSR stratified by 
grade and triple-negative status were comparable with the Nottingham Breast Cancer series. 
The interaction term showed no statistical significant effect for RFS if stratified by grade or 
triple-negative status. A possible explanation of the lack of statistical significance is the 
moderate number of events.  
Thirdly, the prognostic effect of the TSR was not modified by age, tumor size, histology, ER 
status, PR status, HER2 status and lymph node status. This means that the prognostic value of 
the TSR in these clinically relevant subgroups does not differ from the prognostic value of 
the total cohort.  
No former published literature has evaluated the prognostic value of the TSR by introducing 
the interaction term. Therefore, the results are not completely comparable. However, previous 
research showed higher HRs for the TSR in patients with triple-negative tumors as 
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overviewed by Kramer et al. (33). The effect of the TSR stratified by grade has not been 
previously described.   
The next step towards the clinical implementation of the TSR is to investigate the 
discriminating prognostic value of the TSR additional to the commonly used online 
PREDICT tool, which helps oncologists and patients in a shared decision towards 
personalized therapy (37, 38). Therefore, retrospective data will be analyzed and a 
prospective study such as the UNITED (Uniform Noting for International application of the 
Tumor-stroma ratios as Easy Diagnostic Tool) study needs to be performed (39). The 
UNITED study is a prospective international multicenter study initiated by our research 
group. The study aim is to validate and prepare the TSR for implementation in standard 
clinical care in patients with colon cancer. Implementation of TSR assessment in standard 
clinical care has advantages compared to other potential biomarkers as this method is easy to 
perform, takes less than two minutes and requires no additional costs. Therefore, a 
comparable study for breast cancer would be desirable in the next step towards clinical 
implementation. Inter- and intra-observer reliability of the TSR assessment on digital slides 
in colon cancer is also evaluated in the UNITED study. The TSR assessment is explained to 
pathologists and residents via e-learning and tests sets.  
The Nottingham Breast Cancer series is the first study in which the TSR is digitally assessed 
on breast cancer tissue by the method of Mesker et al. (7). For the digital assessment, a field 
of 3.1 mm2 was used for final TSR scoring, which corresponds with conventional light 
microscopy used in our previous research. Van Pelt et al. described that the diameters of the 
different conventional light microscopes are between 2.54 and 3.80 mm2. However, this has 
not led to any major differences in the final score (36). One hundred percent of the slides 
were double scored in a blinded fashion by two observers (KV,WM), instead of the 
customary 30% double scoring, because of the possible learning curve of scoring digitally for 
the first time. The Cohen’s kappa coefficient increased from 0.61 at first assessment to 0.87 
in the second assessment of the slides with an incongruent value at the first time. In our 
opinion, observers who perform digital TSR assessment for the first time need to be aware of 
a learning curve. If this stage is passed, the TSR scoring on digital slides seems to be reliable 
and gives, therefore, good perspective for further digital assessment.  
Furthermore, the intra-tumoral stroma contains valuable prognostic information and may, 
therefore, be an important source for the development of new stroma based therapeutic 
agents. A major component of the tumor associated stroma and therefore a promising 
therapeutic target are CAFs. At the moment, CAFs are still difficult to target due to the lack 
of specific cell surface targets, as they are heterogenous in phenotype and function. An 
important recent finding is the identification of CD10 and GPR77 as surface markers on 
CAFs in breast cancer. CD10+GPR77+ CAFs are predictive for response to chemotherapy and 
patient survival, particularly in breast tumors with a high grade (40). The authors showed that 
the disease-free survival of breast cancer patients with a high CD10+GPR77+ CAF infiltration 
was significantly shorter. The disease-free survival of patients with grade I and grade II 
tumors were independent of CD10+GPR77+ CAF infiltration (6). These results are interesting 
as we found that the prognostic value of TSR is most discriminative in grade III tumors 
compared with grade I and grade II tumors. Whether CAF subtypes differ between stroma-
low and stroma-high tumors is not known at this moment and requires further research.  
Moreover, Ahn and colleagues concluded that, especially in patients with grade III tumors, 
the dominant stroma type was an independent risk factor for disease-free survival in favor for 
patients with lymphocyte dominant stroma (41). Therefore, evaluation of the stromal 
composition would be interesting, for instance by dividing the stromal compartment in 




Advantages of this study are the large cohort size and long follow-up period. A limitation of 
this study is the time period in which patients are included and as a consequence the changes 
in treatment modalities. In the studied patient groups, proportionally less patients received 
hormonal therapy than in current treatments. However, previously published research, 
including the ONCOPOOL study, showed that the TSR was of prognostic value in patients 
with hormone receptor-positive tumors who received hormonal therapy (9,14). This may 
suggest that the prognostic value of the TSR can be translated to current hormonal treatment 
strategies. Also the introduction of Trastuzumab has positively influenced clinical outcome. 
Therefore, a large, more recent retrospective study, in which the change in treatment 
modalities and a decent follow-up period are considered, and/or a prospective cohort study 




The results showed that the prognostic effect of the TSR is most discriminative in grade III 
tumors, compared with grade I and grade II tumors, and in triple-negative tumors, compared 
with non-triple-negative tumors. Furthermore, the prognostic value of the TSR was not 
modified by age, tumor size, histology, ER status, PR status, HER2 status and lymph node 
status. This makes TSR a potential factor for inclusion to improve risk stratification. 
Validating the TSR in a prospective study could further improve clinical decision making 
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Table 1. Overview of the stratification of age and tumor characteristics of the patients 
included in the Nottingham Breast Cancer Series. 
  Stroma-low Stroma-high  
 n n = 681  % n = 1113 %  p-value 
Age (in years) 
<40 144 71 10.4 73 6.6 0.006 
40-<50 385 151 22.2 234 21.0  
50-<60 636 247 36.3 389 35.0  
≥60 628 212 31.1 416 37.4  
Missing 1 0 0.0 1 0.1  
Tumor size (in cm’s) 
≤2 1146 505 74.2 641 57.6 <0.001 
>2-<5 625 169 24.8 456 41.0  
≥5 21 6 0.9 15 1.3  
Missing 2 1 0.1 1 0.1  
Lymph node involvement 
No  1127 452 66.4 675 60.6 0.015 
Yes 664 227 33.3 437 39.3  
Missing 3 2 0.3 1 0.1  
Grade 
I 279 105 15.4 174 15.6 0.606 
II 733 272 39.9 461 41.4  
III 781 303 44.5 478 42.9  
Missing 1 1 0.1 0 0  
Histological type 
Invasive carcinoma of NST 1129 450 66.1 679 61.0 0.117 
Lobular carcinoma 155 53 7.8 102 9.2  
Tubular carcinoma 275 90 13.2 185 16.6  
Others 235 88 12.9 147 13.2  
ER status 
Negative 331 151 22.2 180 16.2 0.001 
Positive 1463 530 77.8 933 83.8  
PR status 
Negative 708 282 41.4 426 38.3 0.262 
Positive 1067 390 57.3 677 60.8  
Missing 19 9 1.3 10 0.9  
HER2 status 
Negative 1573 594 87.2 979 88.0 0.645 
Positive 221 87 12.8 134 12.0  
Triple-negative tumors 
No 1546 560 82.2 986 88.5 0.001 
Yes 235 115 16.9 120 10.8  
Missing 13 6 0.9 7 0.6  
Chemotherapy 
No 699 255 37.4 444 39.9 0.577 
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Yes 292 115 16.9 177 15.9  
Missing 803 311 45.7 492 44.2  
Hormonal therapy  
No 455 182 26.7 273 24.5 0.112 
Yes  778 274 40.2 504 45.3  
Missing 561 225 33.0 336 30.2  
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, NST = no special 





Table 2. Univariate and multivariate analysis of the Nottingham Breast Cancer Series calculated by Cox regression analysis.   
  Recurrence-free survival Breast cancer-specific survival 
  Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
 n HR 95% CI  p-value HR 95% CI p-value HR 95% CI p-value HR  95% CI  p-value 
Age  
 1793 0.99 1.98 to 1.00 0.129 1.00 0.99 to 1.01 0.680 0.99 0.98 to 1.00 0.222 1.01 0.99 to 1.02 0.388 
Tumor size (in cm’s) 
≤2 1146   <0.001   <0.001   <0.001   <0.001 
>2 646 2.17 1.81 to 2.61  1.73 1.42 to 2.11  2.41 1.93 to 3.00  1.70 1.35 to 2.15  
Grade 
I 279   <0.001   <0.001   <0.001   <0.001 
II 733 1.52 1.07 to 2.15  1.24 0.83 to 1.84  2.96 1.66 to 5.29  2.32 1.34 to 4.37  
III 781 2.91 2.09 to 4.06  2.08 1.37 to 3.15   7.01 4.01 to 12.28  4.67 2.46 to 8.88  
Histological type 
Invasive carcinoma of 
NST 
1129   <0.001   0.012   <0.001   0.083 
Lobular carcinoma 155 0.93 0.67 to 1.30  1.30 0.91 to 1.85  0.90 0.61 to 1.32  1.44 0.94 to 2.19  
Tubular carcinoma 275 0.53 0.38 to 0.72  0.98 0.70 to 1.43  0.34 0.22 to 0.53  0.93 0.56 to 1.55  
Others  235 1.16 0.90 to 1.50  1.51 1.16 to 1.97  0.98 0.72 to 1.34  1.41 1.02 to 1.95  
ER status 
Negative 331   <0.001   0.296   <0.001   0.801 
Positive 1463 0.64 0.52 to 0.80  1.16 0.88 to 1.54  0.50 0.39 to 0.63  1.04 0.76 to 1.43  
PR status 
Negative 708   <0.001   0.011   <0.001   0.005 




Negative  1573   <0.001   <0.001   <0.001   0.002 
Positive 221 2.09 1.66 to 2.64  1.70 1.32 to 2.18  2.27 1.74 to 2.96  1.56 1.17 to 2.08  
TSR 
Stroma-low 681   <0.001   0.004   <0.001   0.001 
Stroma-high 1113 1.46 1.19 to 1.78  1.35 1.10 to 1.66  1.60 1.25 to 2.04  1.51 1.18 to 1.95  
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, NST = no special type, PR = progesterone receptor, TSR = tumor-stroma ratio
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Table 3. Results of the independent prognostic value of the tumor-stroma ratio adjusted for 
only confounders or confounders combined with triple-negative status or lymph node status 
calculated with multivariate Cox regression analysis in the Nottingham Breast Cancer series.  
 Recurrence-free survival Breast cancer-specific 
survival 
Confounders HR 1.35, 95% CI 1.10 to 1.66,  
p = 0.004 
HR 1.51, 95% CI 1.18 to 
1.95, p = 0.001 
Confounders including 
triple-negative status 
HR 1.34, 95% CI 1.09 to 1.64,  
p = 0.006 
HR 1.47, 95% CI 1.15 to 
1.90, p = 0.002 
Confounders and lymph 
node status 
HR 1.35, 95% CI 1.10 to 1.66,  
p = 0.004 
HR 1.51, 95% CI 1.17 to 
1.94,  
p = 0.002 
 
 
Table 4. Results of the tumor-stroma ratio stratified by clinically important prognostic 
parameters in the Nottingham Breast Cancer series and the multivariate Cox regression 
analysis per clinically relevant subgroups with a statistically significant difference. 
TSR stratified by 
group 
Subgroups Recurrence-free survival Breast cancer-specific 
survival 
Age  p = 0.881 p = 0.874 
Tumor size  p = 0.422 p = 0.209 
Grade  p < 0.001 p = 0.002 
 Grade I HR 1.16, 95% CI 0.58 to 
2.29, p = 0.670 
HR 6.34, 95% CI 0.81 to 
49.95, p = 0.079 
 Grade II HR 0.78, 95% CI 0.55 to 
1.10, p = 0.152 
HR 0.83, 95% CI 0.54 to 1.30,  
p = 0.422 
 Grade III HR 1.89, 95% CI 1.43 to 
2.51, p < 0.001 
HR 1.86, 95% CI 1.35 to 2.57,  
p < 0.001 
Histological type  p = 0.684 p = 0.951 
ER status  p = 0.088 p = 0.101 
PR status  p = 0.861 p = 0.532 
HER2 status  p = 0.205 p = 0.851 
Triple-negative 
status 
 p = 0.040 p = 0.026 
 Non-triple-
negative status 
HR 1.21, 95% CI 0.97 to 
1.51, p = 0.095 
HR 1.27, 95% CI 0.96 to 1.67,  
p = 0.092 
 Triple-negative 
status 
HR 1.86, 95% CI 1.10 to 
3.14, p = 0.020 
HR 2.24, 95% CI 1.24 to 4.07,  
p = 0.008 
Lymph node status  p = 0.995 p = 0.432 





Supplementary table 1. Overview of the stratification of age, tumor characteristics and 
treatment options of patients included in the ONCOPOOL study. 
  Stroma-low Stroma-high  
 n n = 454 % n = 283 %  p-value 
Age (in years) 
<40  63 49 10.8 14  4.9 0.012 
40-49 206 134 29.5 72  25.4  
50-59 259 147  32.4 112  39.6  




621 386  85.0 235  83.0 0.484 
Lobular carcinoma 69 38  8.4 31  11.0  
Tubular carcinoma 32 22 4.8 10 3.5  
Others 15 8 1.8 7 2.5  
Grade 
I 159 101  22.2 58  20.5 0.274 
II 255 146 32.2 109  38.5  
III 216 142 31.3 74  26.1  
Missing 107 65 14.3 42 14.8  
Tumor size (in cm’s) 
≤2  479 314 69.2 165  58.3 0.005 
>2-≤5 252 135  29.7 117  41.3  
>5 6 5  1.1 1  0.4  
Nodal status 
Negative 416 257 56.6 159  56.2 0.145 
Positive 315 191 42.1 124  43.8  
Missing 6 6 1.3 0 0  
ER status 
Negative 127 87  19.2 40 14.1 0.142 
Positive 606 365  80.4 241 85.2  
Missing 4 2 0.4 2 0.7  
PR status 
Negative 234 149  32.8 85  30.0 0.442 
Positive 496 302  66.5 194  68.6  
Missing 7 3 0.7 4 1.4  
HER2 status 
Negative 573 357  78.6 216 76.3 0.462 
Positive 151 91 20.0 60  21.2  
Missing 13 6 1.3 7 2.5  
Chemotherapy 
No 573 346  76.2 227  80.2 0.204 
Yes 164 108  23.8 56  19.8  
Hormonal therapy 
No 369 229  50.4 140 49.5 0.798 
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Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, NST = no special 





























Yes 368 225  49.6 143  50.5  
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Supplementary table 2. Univariate and multivariate Cox regression analysis of the ONCOPOOL study. The tumor-stroma ratio is adjusted for 
confounders.  
  Recurrence-free survival Overall survival 
  Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
 n HR 95% CI   p-value HR 95% CI  p-value HR 95% CI  p-value HR  95% CI  p-value 
Age  
 733 1.00 0.98 to 1.01 0.482 1.00 0.98 to 1.02 0.978 1.04 1.03 to 1.05 <0.001 1.04 1.03 to 1.06 <0.001 
Tumor size (in cm’s) 
≤2 479   <0.001   0.098   <0.001   0.028 
>2 258 1.77 1.35 to 2.32  1.31 0.95 to 1.79  1.65 1.30 to 2.09  1.37 1.04 to 1.82  
Grade 
I 159   <0.001   0.022   <0.001   0.001 
II 255 1.86 1.22 to 2.86  1.63 1.04 to 2.56  1.64 1.13 to 2.38  1.65 1.10 to 2.46  
III 216 2.51 1.64 to 3.85  2.00 1.22 to 3.28   2.47 1.71 to 3.56  2.24 1.46 to 3.43  
Histological type 
Invasive carcinoma of 
NST 
621   0.657   0.464   0.461   0.326 
Lobular carcinoma 69 0.99 0.63 to 1.56  1.32 0.74 to 2.35  0.93 0.62 to 1.40  1.11 0.63 to 1.97  
Tubular carcinoma 32 0.69 0.32 to 1.47  0.92 0.39 to 2.15  0.93 0.53 to 1.63  1.02 0.52 to 2.00  
Others  14 0.61 0.19 to 1.91  0.41 0.10 to 1.67  0.40 0.13 to 1.26  0.16 0.02 to 1.15  
ER status 
Negative 127   <0.001   0.542   <0.001   0.470 
Positive 606 0.55 0.40 to 0.76  0.87 0.55 to 1.37  0.54 0.41 to 1.71  0.87 0.59 to 1.27  
PR status 
Negative 234   <0.001   0.271   <0.001   0.016 
Positive 496 0.60 0.45 to 0.79  0.81 0.55 to 1.18  0.51 0.40 to 0.64  0.67 0.49 to 0.93  
HER2 status 
Negative  573   0.572   0.896   0.017   0.033 




Stroma-low 454   0.093   0.085   0.016   0.029 
Stroma-high 283 1.26 0.96 to 1.66  1.30 0.96 to 1.76  1.34 1.06 to 1.69  1.35 1.03 to 1.77  













Supplementary table 3. Results of the independent prognostic value of the tumor-stroma 
ratio adjusted for confounders, triple-negative status and lymph node status calculated with 






Supplementary table 4. Results of tumor-stroma ratio stratified by clinically important 
prognostic parameters in the ONCOPOOL study and the multivariate Cox regression analysis 
per clinically relevant subgroup with a statistically significant difference in the Nottingham 
Breast Cancer series. 
TSR stratified 
by group 
Subgroups Recurrence-free survival Overall survival 
Age  p = 0.496 p = 0.840 
Tumor size  p = 0.816 p = 0.823 
Grade  p = 0.122 p = 0.414 
 Grade I HR 0.92, 95% CI 0.39 to 
2.35,  
p = 0.992 
HR 0.83, 95% CI 0.38 to 
1.81, p = 0.631 
 Grade II HR 1.06, 95% CI 0.66 to 
1.70,  
p = 0.806 
HR 1.30, 95% CI 0.83 to 
2.02, p = 0.257 
 Grade III HR 1.86, 95% CI 1.18 to 
2.93,  
p = 0.008 
HR 1.61, 95% CI 1.08 to 
2.41, p = 0.020 
Histological type  p = 0.838 p = 0.620 
ER status  p = 0.445 p = 0.222 
PR status  p = 0.982 p = 0.387 
HER2 status  p = 0.646 p = 0.910 
Triple-negative 
status 
 p = 0.343 p = 0.255 
 Non-triple-
negative status 
HR 1.25, 95% CI 0.91 to 
1.73,  
p = 0.176 
HR 1.28, 95% CI 0.96 to 
1.72, p = 0.093 
 Triple-negative 
status 
HR 1.54, 95% CI 0.64 to 
3.66, 
p = 0.333 
HR 1.75, 95% CI 0.83 to 
3.66, p = 0.140 
Lymph node 
status 
 p = 0.423 p = 0.097 
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor, PR = progesterone 
receptor 
 Recurrence-free survival Overall survival 
Confounders HR 1.30, 95% CI 0.96 to 
1.76, p = 0.085 
HR 1.35, 95% CI 1.03 to 
1.77, p = 0.029 
Confounders including 
triple-negative status 
HR 1.30, 95% CI 0.96 to 
1.75, p = 0.091 
HR 1.34, 95% CI 1.02 to 
1.74, p = 0.033 
Confounders and lymph 
node status 
HR 1.28, 95% CI 0.95 to 
1.73, p = 0.112 
HR 1.33, 95% CI 1.02 to 
1.74, p = 0.037 
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Figure 1. Kaplan-Meier analysis for recurrence-free survival of patients included in the 













Figure 2. Kaplan-Meier analysis for recurrence-free survival of patients included in the 
Nottingham Breast Cancer Series stratified by tumor-stroma ratio combined with triple-













Supplementary figure 1. Representative tissue selection for tumor-stroma ratio assessment. 
















Supplementary figure 2. Kaplan-Meier analysis for recurrence-free survival of patients 
included in the Nottingham Breast Cancer Series stratified by tumor-stroma ratio. 
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